Last patient enrolls in phase 2 trial with Transgene’s TG4010 + nivolumab + chemotherapy for first-line treatment of advanced NSCLC

Image: Last patient has been enrolled in phase 2 trial with Transgene’s TG4010 + nivolumab + chemotherapy for first-line treatment of advanced NSCLC. Photo: courtesy of Colin Behrens / Pixabay.